New Three-Drug attack on tough sarcomas enters key test

NCT ID NCT05836571

Summary

This study is testing if a three-drug combination works better than a two-drug immunotherapy approach to control advanced soft tissue sarcoma. It will involve about 66 adults with specific types of sarcoma that have spread or cannot be surgically removed. The goal is to see if adding the drug cabozantinib to the immunotherapy drugs ipilimumab and nivolumab can slow or stop cancer growth more effectively.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Keck Medicine of USC Koreatown

    Los Angeles, California, 90020, United States

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York, 10016, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland, 20892, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, 63129, United States

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut, 06105, United States

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut, 06611, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California, 92612, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California, 92663, United States

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • University of Florida Health Science Center - Gainesville

    Gainesville, Florida, 32610, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.